{ "model": "qwen/qwen3.6-35b-a3b", "started_at": "2026-05-19T03:58:28.391Z", "system_prompt": "You are Analyst, the thesis-judgment stage of an AI trade-ideas pipeline.\n\nScout has already gathered a JSON dossier of scoring_inputs. Your job is to\nSCORE the dossier against the methodology rubric and either draft an idea\n(if score ≥ 60) or skip.\n\nOPTION B (skip) IS THE EXPECTED DEFAULT. The pipeline publishes rarely and\nonly when something clears a high bar. Most dossiers should return\n{ \"skip\": true, \"reason\": \"...\", \"score\": }. Mediocre publishes burn\nDevil's Advocate budget and create credibility risk on the public site.\n\nLOOK AT THE FULL STRUCTURE MENU. Even when Scout says 'no asymmetric long\nopportunity exists' (verdict=range_bound_or_income), there may be a clear\nINCOME structure (covered call against the high; strangle inside an IV-\nelevated band; CSP at a downside-defended strike). Don't reflex-skip just\nbecause long_stock isn't attractive. Read the dossier looking for what\nSHAPE OF TRADE fits, not just whether long is fits.\n\nSCORING RUBRIC (sum to max 100)\n\nA. SMART-MONEY CLUSTER (max 25) — from scoring_inputs.smart_money\n • 10 pts if 3+ distinct insiders with open-market purchases (code P) in\n last 90 days totaling ≥ $500K\n • +3 pts if CEO is among the buyers\n • +3 pts if CFO is among the buyers\n • +2 pts if total purchases > $5M\n • 5 pts for a known concentrated 13F initiation/add (Berkshire, Pershing\n Square, Appaloosa, Greenlight, Scion, Polen, Pabrai, Tepper, etc.)\n • +3 pts if it's in the manager's top-3 positions\n • 2 pts for politician STOCK Act recent buy\n • +1 pt if multiple unrelated members bought within 30 days\n • Penalty: −10 pts if material insider SELLING > BUYING in dollars\n\nB. OPTIONS FLOW / UOA (max 10) — from scoring_inputs.options_flow\n • 4 pts: whale_call_blocks_otm ≥ 2 with flow_directional_bias = bullish\n and flow_strength ∈ {moderate, strong}\n • 3 pts: bullish IV skew (call IV > put IV) consistent with thesis\n • 2 pts: net_dollar_bias_pct > 30 (sustained call-side flow)\n • 1 pt: large OI building at a defended price level\n • Penalty: −5 pts if whale_put_blocks_otm ≥ 2 and bias is bearish\n without a hedging explanation\n\nC. CATALYST (max 25) — from scoring_inputs.catalyst\n • 10 pts: earnings within 90 days AND last 4 quarters' EPS surprise > 0%\n • 8 pts: pending product launch / FDA / contract milestone in horizon\n • 5 pts: recent guidance raise (last 90 days)\n • 5 pts: quantifiable sector tailwind (named hyperscaler capex flowing\n to this name in $)\n Cap at 25 even if components add to more.\n\nD. MISPRICING (max 15) — from scoring_inputs.mispricing\n • 5 pts: forward P/E ≥ 20% below sector median (with non-deteriorating\n earnings)\n • 4 pts: EV/EBITDA ≥ 30% below sector median\n • 4 pts: FCF yield ≥ 7% with stable FCF\n • 5 pts: SOTP gap ≥ 25% (replaces one of the above)\n Cap at 15.\n\nE. QUALITY (max 15) — from scoring_inputs.quality\n • 5 pts: ROIC ≥ 15% (or trending there)\n • 5 pts: gross margin expanding ≥ 3pp YoY\n • 5 pts: net debt / EBITDA ≤ 2x (or net cash)\n\nF. MOMENTUM/TECHNICAL (max 10) — from scoring_inputs.technical\n • 3 pts: above both 50DMA and 200DMA\n • 4 pts: 12-1 month price return positive AND beating sector\n • 2 pts: RSI 14 in 40-65 zone\n • 1 pt: MACD bullish cross in last 30 days\n\nRISK CLASS — choose one based on the dossier's market_cap field:\n \"core\" — market_cap > $5B. Standard methodology sizing.\n \"asymmetric\" — market_cap ≤ $5B (small-cap moonshot). 90%+ of these\n bets lose money or go to zero; the few that work pay\n for the rest. Position sizing is far more conservative\n to fit the variance.\n\nTHRESHOLDS — depend on risk_class\n\n CORE risk_class:\n ≥ 80 Publish, confidence 5, position size cap 4-5%\n 70-79 Publish, confidence 4, position size cap 2.5-3.0%\n 60-69 Publish, confidence 3, position size cap 1.5-2.0%\n 50-59 Skip unless catalyst <30d + insider cluster\n < 50 Skip\n\n ASYMMETRIC risk_class — strict sizing:\n ≥ 80 Publish, confidence 5, position size cap 1.5%\n 70-79 Publish, confidence 4, position size cap 1.0%\n 60-69 Publish, confidence 3, position size cap 0.5%\n < 60 Skip (no exception; small caps need a clear catalyst)\n Structure must be long_stock (options structures are wrong shape for\n moonshots; Compliance enforces this in code).\n\nANTI-SIGNAL GATES (any one of these forces skip regardless of score):\n • Going-concern audit qualification\n • Pending material litigation (DOJ/SEC enforcement, class action with merit)\n • Customer concentration > 30%\n • Convertible/warrant overhang creating dilution > 10% of float\n • Accounting irregularities (restatements, auditor changes)\n • Avg daily volume < $5M (liquidity gate)\n • Pump-and-dump signals (sudden volume + chat-room mentions)\n\nIf scoring_inputs has anti_signals_present non-empty, treat each entry as a\ngate; skip unless you can articulate WHY it doesn't apply to this case.\n\nEDGE CHECK (philosophical, not numeric)\n\nAfter scoring, ask: \"What does this idea say that the market doesn't already\nknow?\" If the answer is generic (it's cheap, AI is a tailwind, technicals\nlook great), the score is misleading — skip even if numerical score is 65.\nReal edge means a specific data point or interpretation the market missed.\n\nSCOUT VERDICT → STRUCTURE GUIDANCE\n\nRead scoring_inputs and Scout's verdict together. The verdict tells you\nWHICH structures Scout thinks are in scope for this name:\n\n verdict='promising' → long_stock | csp (for asymmetric long)\n verdict='range_bound_or_income' → cc | strangle | csp on pullback\n (DON'T default to long_stock — Scout\n already said this isn't an asymmetric\n long. Look at IV elevated → strangle;\n stock at 52w high, fundamentals healthy\n → cc against implicit long; pullback\n thesis with cash → csp)\n verdict='bearish_setup' → naked_call (rarely; respect ceiling)\n\nIf Scout supplied structure_hints[], they're a starting point. You can\noverride with reasoning, but if you go OUTSIDE the verdict's natural set,\nexplain why in thesis_long.\n\nSTRUCTURE SELECTION — full menu:\n\n long_stock — multi-quarter asymmetric thesis, IV not elevated, want\n full upside participation\n csp — bullish, want to own at strike, IV elevated, ann yield ≥15%\n cc — range-bound or mildly bullish, IV elevated, on top of long\n stock leg, if-called return ≥15% ann\n strangle — RANGE-BOUND thesis with elevated IV. Sell OTM call + OTM\n put. Need: comfortable owning at put_strike, no parabolic\n upside expectation. Ann yield ≥12%. Compute and emit\n breakeven_high (call_strike + total_premium) and\n breakeven_low (put_strike - total_premium).\n naked_put — same setup as CSP but using margin. ~2x yield, margin call\n risk. Only for margin-equipped accounts. Note explicitly.\n naked_call — bearish setup with elevated IV. UNCAPPED loss if rally.\n Confidence ceiling 4 (Compliance enforces). Requires\n explicit upside-shock thesis + defense plan in conditions.\n\nMatch the structure to the thesis shape — don't reach for naked options\njust because the premium is fatter. Most candidates are best as long_stock\nor CSP. Strangles only when you have a clear range thesis backed by IV\nand fundamentals.\n\nIF YOU SKIP — output exactly:\n {\n \"skip\": true,\n \"score\": <0-100 composite>,\n \"score_breakdown\": {\n \"smart_money\": <0-25>, \"options_flow\": <0-10>, \"catalyst\": <0-25>,\n \"mispricing\": <0-15>, \"quality\": <0-15>, \"technical\": <0-10>\n },\n \"reason\": \"1-2 sentences why this dossier doesn't support a thesis.\"\n }\n\nIF YOU PROCEED — output a draft idea matching this schema (this is the same\nschema the published site renders from):\n\n{\n \"skip\": false,\n \"score\": <0-100 composite>,\n \"score_breakdown\": {\n \"smart_money\": <0-25>, \"options_flow\": <0-10>, \"catalyst\": <0-25>,\n \"mispricing\": <0-15>, \"quality\": <0-15>, \"technical\": <0-10>\n },\n \"draft\": {\n \"slug\": \"YYYY-MM-DD-symbol-keyphrase\",\n \"symbol\": \"TICKER\",\n \"company\": \"Full name\",\n \"sector\": \"semis-ai-infra\" | \"small-cap-asymmetric\",\n \"risk_class\": \"core\" | \"asymmetric\",\n \"headline\": \"Punchy 1-line — the news angle on the thesis\",\n \"thesis_short\": \"1 sentence — why this trade exists.\",\n \"thesis_long\": [\n \"Opening paragraph framing the setup.\",\n \"## Catalyst\",\n \"Detailed catalyst narrative.\",\n \"## Why the market is mispricing this\",\n \"Edge explanation, citing dossier facts.\",\n \"## Numbers\",\n \"- Bullet 1 with concrete numbers from the dossier\",\n \"- Bullet 2\",\n \"## Risk\",\n \"Honest description of what could go wrong.\"\n ],\n \"structure\": {\n \"type\": \"long_stock\" | \"csp\" | \"cc\" | \"strangle\" | \"naked_put\" | \"naked_call\",\n \"long_stock\": { \"entry_zone_low\": , \"entry_zone_high\": , \"shares_per_unit\": 100 },\n \"csp\": { \"strike\": , \"expiry\": \"YYYY-MM-DD\", \"premium_target\": , \"annualized_yield_pct\": , \"if_assigned_basis\": },\n \"cc\": { \"underlying_basis\": , \"strike\": , \"expiry\": \"YYYY-MM-DD\", \"premium_target\": , \"if_called_return_pct\": },\n \"strangle\": { \"call_strike\": , \"put_strike\": , \"expiry\": \"YYYY-MM-DD\", \"call_premium_target\": , \"put_premium_target\": , \"total_premium_target\": , \"breakeven_high\": , \"breakeven_low\": , \"annualized_yield_pct\": , \"max_loss_note\": \"...\" },\n \"naked_put\": { \"strike\": , \"expiry\": \"YYYY-MM-DD\", \"premium_target\": , \"annualized_yield_pct\": , \"max_loss_per_contract\": , \"margin_estimate_per_contract\": , \"warning\": \"...\" },\n \"naked_call\": { \"strike\": , \"expiry\": \"YYYY-MM-DD\", \"premium_target\": , \"annualized_yield_pct\": , \"max_loss\": \"UNLIMITED\", \"warning\": \"...\" }\n },\n \"entry\": {\n \"price_at_idea\": ,\n \"conditions\": \"How/when to enter — e.g., 'Open starter on pullback to MA50.'\"\n },\n \"exit\": {\n \"target_price\": ,\n \"time_horizon_months\": ,\n \"stop_conditions\": \"Specific signal(s) that trigger a close.\"\n },\n \"risk\": {\n \"bear_case\": \"Honest, specific bear case (not generic 'market could fall').\",\n \"what_breaks_thesis\": \"Specific event/data that invalidates the call.\",\n \"position_size_pct\": <0.5 to 5.0, conviction-weighted>\n },\n \"sources\": [\n { \"label\": \"...\", \"url\": \"...\" }\n ],\n \"confidence\": <1-5, conservative>,\n \"analyst\": \"research-desk\",\n \"scout_model\": \"minimax/minimax-m2.7\",\n \"analyst_model\": \"qwen/qwen3.6-35b-a3b\",\n \"devils_advocate_verdict\": null\n }\n}\n\nONLY ONE STRUCTURE TYPE. Pick long_stock, csp, OR cc and only fill that\nsub-object. Leave the others null/omitted.\n\nALL NUMBERS must be drawn from the dossier or computable from it. Do not\ninvent prices, strikes, premiums.\n\nOUTPUT ONLY VALID JSON. No surrounding prose, no markdown fences.", "user_prompt": "Here is the dossier from Scout. Decide: skip or draft.\n\n\nLESSONS LEARNED: none yet.\n\nDOSSIER:\n{\n \"symbol\": \"VEEV\",\n \"company\": \"Veeva Systems Inc.\",\n \"investigation_summary\": \"VEEV has been crushed ~42% YTD from its October 2025 high of $310 to $163.85 — a massive de-rating driven by macro headwinds (rising rates hitting growth multiples) and sector rotation out of high-P/E SaaS names. The stock now trades at just 16.6x forward P/E vs. its historical 40-50x range, sitting nearly 47% below the 52-week high with a PEG ratio of only 0.73 (sub-1 suggests undervaluation relative to growth). Earnings on June 3 are a clear near-term catalyst: Q4 FY2026 beat by +13%, and Q1 estimates look achievable given consistent positive guidance history. New CRM wins (Roche, BioMarin), the Ostro AI acquisition, Smith+Nephew Quality Cloud deal, and Snowflake partnership all show continued product momentum. Insiders are absent as buyers — only scheduled 10b5-1 selling via a director sale at $155.64 in late April. The options market is moderately bullish (54.8% call bias, new positioning at $150 strike with V/OI=1.6), and IV is elevated (~60%) around the earnings event. No structural edge found in filings that isn't already public.\",\n \"verdict\": \"range_bound_or_income\",\n \"confidence_in_data\": 5,\n \"structure_hints\": [\n \"cc\",\n \"strangle\",\n \"csp\"\n ],\n \"business_snapshot\": \"Veeva Systems is the dominant cloud platform for the global life sciences industry, serving pharma, biotech, and medtech companies across drug development (Clinical, RIM, Safety), quality management (Quality Cloud), commercial operations (Vault CRM), and data/analytics. It operates four cloud suites built on its proprietary Veeva Vault platform and has been expanding aggressively into AI agents post-Ostro acquisition in late 2025. The company generates ~$3.2B in annual revenue with ~75% gross margins and ~29-31% operating margins, holding $6.56B in cash against minimal debt ($95M). Its customer base includes virtually all top-20 global pharmaceutical companies, creating a sticky recurring-revenue moat. FY2026 (ended Jan 2026) was a strong year with revenue up ~16% and net income growth of ~23%. The company operates as a Delaware public benefit corporation.\",\n \"scoring_inputs\": {\n \"smart_money\": {\n \"insider_open_market_purchases_90d\": [],\n \"insider_open_market_total_usd_90d\": 0,\n \"distinct_insider_buyers_90d\": 0,\n \"ceo_buy_present\": false,\n \"cfo_buy_present\": false,\n \"material_insider_selling_90d_usd\": 116730\n },\n \"notable_13f_holders\": [\n \"pending — v2\"\n ],\n \"politician_recent_buys\": [\n \"pending — v2\"\n ]\n },\n \"catalyst\": {\n \"next_earnings_date\": \"2026-06-03\",\n \"recent_eps_surprise_pattern\": \"4 consecutive beats: +13.0% (Q3 FY26), +4.8% (Q2 FY26), +4.6% (Q1 FY26), +6.5% (Q4 FY26 most recent). Consistent positive guidance history.\",\n \"guidance_raise_in_last_90d\": true,\n \"named_catalysts\": [\n {\n \"type\": \"earnings\",\n \"description\": \"Q1 FY2027 earnings release, fiscal year 2026 ended Jan 2026 — next quarterly report after strong FY close\",\n \"date_or_window\": \"2026-06-03 post-market with 2pm PT conference call\",\n \"source_urls\": [\n \"https://finance.yahoo.com/news/veeva-release-fiscal-2027-first-200500646.html\"\n ],\n \"directional_bias\": \"bullish\"\n },\n {\n \"type\": \"product\",\n \"description\": \"Vault CRM momentum: Roche and BioMarin signed, Ostro AI acquisition integration underway with agentic capabilities\",\n \"date_or_window\": \"Q4 FY2026 (ended Jan 2026) and ongoing through Q1 FY2027\",\n \"source_urls\": [\n \"https://finance.yahoo.com/sectors/healthcare/articles/veeva-systems-expands-ai-vault-142200006.html\"\n ],\n \"directional_bias\": \"bullish\"\n },\n {\n \"type\": \"partnership\",\n \"description\": \"Smith+Nephew adopts Veeva Quality Cloud globally — strategic quality management foundation for global medtech player\",\n \"date_or_window\": \"Early May 2026 announcements (May 11-13)\",\n \"source_urls\": [\n \"https://finance.yahoo.com/sectors/healthcare/articles/smith-nephew-establishes-unified-quality-110300345.html\"\n ],\n \"directional_bias\": \"bullish\"\n },\n {\n \"type\": \"partnership\",\n \"description\": \"Snowflake collaboration connecting Veeva Vault Platform to Snowflake AI Data Cloud for Healthcare & Life Sciences\",\n \"date_or_window\": \"Announced May 6, 2026 via Snowflake's platform disclosure\",\n \"source_urls\": [\n \"https://finance.yahoo.com/markets/stocks/articles/why-veeva-systems-veev-strengthening-060435161.html\"\n ],\n \"directional_bias\": \"bullish\"\n },\n {\n \"type\": \"sector\",\n \"description\": \"Veeva Commercial Summit (May 19-20, Boston) featuring leaders from argenx, Bayer, Boehringer Ingelheim, Genentech, Gilead, GSK, Merck, Novo Nordisk — industry validation event just ahead of earnings\",\n \"date_or_window\": \"May 19-20, 2026\",\n \"source_urls\": [\n \"https://finance.yahoo.com/sectors/healthcare/articles/veeva-commercial-summit-feature-biopharmas-110300209.html\"\n ],\n \"directional_bias\": \"ambiguous\"\n }\n ]\n },\n \"mispricing\": {\n \"forward_pe\": 16.58,\n \"sector_median_forward_pe\": null,\n \"ev_to_ebitda\": 20.7,\n \"sector_median_ev_to_ebitda\": null,\n \"fcf_yield_pct\": 3.92,\n \"sotp_gap_pct\": null,\n \"narrative\": \"VEEV trades at 16.6x forward P/E vs. its own historical range of 40-55x during growth periods and the broader SaaS/healthcare software peer set where comparable companies trade at 25-35x fwd P/E. The stock has de-rated from ~50x to ~17x in less than a year without any fundamental deterioration — Q4 beat by +13% with revenue up 16% YoY. PEG of 0.73 suggests growth is underpriced relative to valuation multiple. At analyst consensus target of $264, the stock would need only to revert halfway toward prior multiples.\"\n },\n \"quality\": {\n \"roic_pct\": null,\n \"gross_margin_trend_pp_yoy\": \"~75% stable\",\n \"net_debt_to_ebitda\": null,\n \"balance_sheet_grade\": \"A\"\n },\n \"technical\": {\n \"above_50dma\": false,\n \"above_200dma\": false,\n \"rsi_14\": 49.2,\n \"macd_recent_bullish_cross\": true,\n \"12_1_momentum_vs_sector_pct\": null\n },\n \"price_context\": {\n \"last_close\": 163.85,\n \"ytd_return_pct\": -42,\n \"from_52w_high_pct\": -47.2\n },\n \"filings_reviewed\": [\n {\n \"form\": \"10-K\",\n \"filed\": \"2026-03-20\",\n \"url\": \"https://www.sec.gov/Archives/edgar/data/1393052/000139305226000014/veev-20260131.htm\",\n \"key_takeaways\": [\n \"FY2026 revenue $3.195B (+16% YoY), net income ~$909M (+23% YoY). Strong beat in Q4 with EPS $2.06 vs. estimate of $1.94 (+6.5%). Gross margins ~75%, operating margin ~29%. Cash and investments: $6.56B. Ostro acquisition closed March 10, 2026 for AI/data capabilities. Vault CRM momentum building — next-gen platform replacing legacy Salesforce-based Veeva CRM (supported through Dec 31, 2029). Risk factors include customer concentration risk (one unnamed top-5 pharma is material). R&D spend growing but stable as % of revenue.\"\n ]\n },\n {\n \"form\": \"10-Q\",\n \"filed\": \"2025-11-21\",\n \"url\": \"https://www.sec.gov/Archives/edgar/data/1393052/000139305225000078/veev-20251031.htm\",\n \"key_takeaways\": [\n \"Q3 FY2026 (Oct 31, 2025): revenue $811M (+16% YoY), subscription services $682.5M. Gross margin 75.4%. Operating income $240.9M (+33% YoY). Total deferred revenue: $822.5M vs. $1.274B at FY start — seasonality in contract timing. R&D expense as % of revenue increased slightly to 24%. Tom Schwenger and Priscilla Hung appointments noted.\"\n ]\n },\n {\n \"form\": \"8-K\",\n \"filed\": \"2026-04-20\",\n \"url\": \"https://www.sec.gov/Archives/edgar/data/1393052/000139305226000018/veev-20260420.htm\",\n \"key_takeaways\": [\n \"General Counsel Josh Faddis announces retirement effective Nov 1, 2026 — successor to be named. Non-critical leadership transition risk but notable at a mid-cap company.\"\n ]\n },\n {\n \"form\": \"8-K\",\n \"filed\": \"2026-03-04\",\n \"url\": \"https://www.sec.gov/Archives/edgar/data/1393052/000139305226000007/veev-20260304.htm\",\n \"key_takeaways\": [\n \"Q4 FY2026 and full-year earnings release — solid beat confirming strong FY close.\"\n ]\n }\n ],\n \"options_context\": {\n \"expiries_examined\": [\n \"2026-06-18\"\n ],\n \"iv_summary\": \"ATM IV at June 18 expiry: ~60-65% range. Put skew steeper than call skew in absolute terms (deeper ITM puts have lower IV than OTM calls), but overall elevated for a large-cap SaaS name — typical pre-earnings ramp.\",\n \"notable_skew_or_flow\": \"Net bull bias: $943K net call notional vs. put (54.8% directional). New positioning at $150 strike, 434 contracts, V/OI=1.6 (highest on the chain for new positions), suggesting notable build of in-the-money calls near current spot ($163.85 — so just below ATM). Top OTM put: $150 strike with 1,710 open interest = largest single concentration. This is a significant put wall that could cap downside and attract buyers to sell cash-secured puts nearby.\"\n },\n \"competitive_landscape\": \"Veeva competes at the intersection of life sciences SaaS. Primary competitors include IQVIA (traditional pharma services/IT), Salesforce Health Cloud, SAP for regulated industries, and point solutions like Medidata (Dassault Systèmes). Veeva's moat is vertical focus — its Vault platform is purpose-built for regulated pharmaceutical workflows, creating deep switching-cost locks with top-20 global pharma. No horizontal SaaS player can easily displace it without rebuilding compliance-specific architecture from scratch.\",\n \"key_risks\": [\n \"Stock de-rated ~47% from 52-week high — could continue under macro pressure (rising rates)\",\n \"Legacy Salesforce-based Veeva CRM still material revenue stream; Vault CRM transition carries execution risk\",\n \"General Counsel retirement announced effective Nov 2026, successor not named yet\",\n \"Customer concentration: at least one top-5 pharma customer represents >10% of accounts receivable\",\n \"Rising Treasury yields compress valuations for high-P/E growth names — VEEV's discount to historical multiples may widen further\",\n \"R&D growing faster than revenue in absolute terms — margin compression risk if top-line slows\",\n \"International expansion slower than expected (Europe/APAC growth rates need monitoring)\"\n ],\n \"what_the_market_might_be_missing\": \"The 42% drawdown is almost entirely multiple compression (~50x to ~17x forward P/E), not fundamental deterioration. Revenue grew 16%, earnings 23%. The stock now has a PEG of 0.73 — meaning the market is pricing in meaningful deceleration that hasn't materialized. New Vault CRM wins (Roche, BioMarin) demonstrate competitive displacement is working even as analysts question AI/CRM commitments. Ostro acquisition adds proprietary healthcare data/intelligence layer not yet reflected in estimates.\",\n \"anti_signals\": [\n \"dilution\",\n \"low_liquidity\"\n ],\n \"sources\": [\n {\n \"label\": \"VEEV 10-K FY2026\",\n \"url\": \"https://www.sec.gov/Archives/edgar/data/1393052/000139305226000014/veev-20260131.htm\"\n },\n {\n \"label\": \"VEEV Q3 FY2026 10-Q\",\n \"url\": \"https://www.sec.gov/Archives/edgar/data/1393052/000139305225000078/veev-20251031.htm\"\n },\n {\n \"label\": \"Form 4 - Priscilla Hung (director sale, April 30 2026)\",\n \"url\": \"https://www.sec.gov/Archives/edgar/data/1393052/000162828026029800/xslF345X06/wk-form4_1777925243.xml\"\n },\n {\n \"label\": \"Earnings press release via Yahoo Finance\",\n \"url\": \"https://finance.yahoo.com/news/veeva-release-fiscal-2027-first-200500646.html\"\n },\n {\n \"label\": \"Smith+Nephew Veeva Quality Cloud announcement\",\n \"url\": \"https://finance.yahoo.com/sectors/healthcare/articles/smith-nephew-establishes-unified-quality-110300345.html\"\n },\n {\n \"label\": \"Vault CRM momentum / AI expansion article\",\n \"url\": \"https://finance.yahoo.com/sectors/healthcare/articles/veeva-systems-expands-ai-vault-142200006.html\"\n }\n ],\n \"unfetched_signals\": [\n \"13f_deltas\",\n \"politician_trades\",\n \"sentiment_score\"\n ]\n}\n\nOutput ONLY the decision JSON described in the system prompt. Do NOT\ninclude ... reasoning blocks — they eat the output token\nbudget and produce truncated, unparseable decisions.", "completions": [ { "ts": "2026-05-19T03:59:07.955Z", "raw_content": "The dossier is for VEEV (Veeva Systems Inc.).\nScout verdict: `range_bound_or_income`.\nStructure hints: `cc`, `strangle`, `csp`.\nAnti-signals: `dilution`, `low_liquidity`.\nMarket cap: Not explicitly given, but price is $163.85. VEEV is a large-cap SaaS (~$25B+ historically, but let's check: $3.2B revenue, ~30x rev multiple historically, so market cap ~$25B. Actually, at 16.6x Fwd PE and ~$3.2B rev, EPS ~$10, so market cap ~$25B. It's definitely >$5B, so `core` risk class.\nWait, the prompt says \"market_cap field\" for risk class. It's not in the JSON, but VEEV is a well-known large-cap. I will classify as `core`.\n\nLet's score according to the rubric.\nA. SMART-MONEY CLUSTER (max 25)\n- insider purchases: 0\n- CEO/CFO buy: false\n- 13F: pending\n- Politician: pending\n- Insider selling: $116,730 (not > buying, but 0 buying)\nScore: 0.\n\nB. OPTIONS FLOW / UOA (max 10)\n- IV elevated (~60-65%) around earnings.\n- Call bias 54.8%, net call notional $943K.\n- New positioning at $150 strike (ITM calls), put wall at $150.\n- No whale call blocks mentioned.\nScore: 1 (large OI building at defended level $150). Maybe 2 for net dollar bias? It says 54.8% directional, net $943K. Not >30% of total? Hard to say. I'll give 2.\n\nC. CATALYST (max 25)\n- Earnings within 90 days (June 3, 2026). Last 4 quarters EPS surprise > 0% (all positive: +13, +4.8, +4.6, +6.5). -> 10 pts.\n- Recent guidance raise (last 90d): true. -> 5 pts.\n- Named catalysts: product, partnerships. -> 5 pts.\nTotal: 20 pts. Cap at 25. I'll give 20.\n\nD. MISPRICING (max 15)\n- Forward P/E: 16.6x vs sector median null. But narrative says \"vs broader SaaS/healthcare software peer set where comparable companies trade at 25-35x fwd P/E.\" That's >20% below. -> 5 pts.\n- EV/EBITDA: 20.7x. Sector median null. Can't confirm 30% below. -> 0.\n- FCF yield: 3.92%. Not >= 7%. -> 0.\n- SOTP: null.\nTotal: 5 pts.\n\nE. QUALITY (max 15)\n- ROIC: null. -> 0.\n- Gross margin: ~75% stable (not expanding >= 3pp). -> 0.\n- Net debt/EBITDA: minimal debt ($95M) vs $6.56B cash. Net cash. -> 5 pts.\nTotal: 5 pts.\n\nF. MOMENTUM/TECHNICAL (max 10)\n- Above 50DMA: false. Above 200DMA: false. -> 0.\n- 12-1 momentum: null. -> 0.\n- RSI 14: 49.2 (in 40-65 zone). -> 2 pts.\n- MACD bullish cross: true. -> 1 pt.\nTotal: 3 pts.\n\nTotal Score: 0 + 2 + 20 + 5 + 5 + 3 = 35.\nWait, let's re-evaluate D. Forward P/E 16.6 vs peer 25-35. That's >20% below. So 5 pts.\nQuality: Net cash gives 5.\nCatalyst: 20.\nOptions: 2.\nMomentum: 3.\nTotal: 35.\n\nAnti-signals: `dilution`, `low_liquidity`.\nVeeva has a history of stock-based compensation (SBC) dilution, but is it >10% of float? Probably not material enough to skip, but it's a flag. Low liquidity? VEEV avg daily volume is usually > $20M, so `low_liquidity` might be a false positive from scout or refers to options liquidity. I'll note it but it doesn't strictly force a skip unless volume < $5M. VEEV is highly liquid. I will ignore the anti-signal as a scout error or non-material, but it lowers confidence.\n\nActually, the score is 35. This is well below 50.\nThresholds for CORE:\n< 50: Skip.\nReason: Score 35. Lacks insider buying, technicals are broken (below 50/200 DMA), and while valuation is historically cheap, the macro headwinds and lack of momentum/flow justify a skip. The dossier itself notes \"No structural edge found in filings that isn't already public.\" and anti-signals flag dilution/liquidity.\n\nLet's double check the scoring.\nA: 0\nB: 2\nC: 20\nD: 5\nE: 5\nF: 3\nSum: 35.\n\nEven if I'm generous on D (maybe 10 for P/E gap?), it only gets to 40.\nThe dossier explicitly says \"No structural edge found in filings that isn't already public.\" and Scout verdict is `range_bound_or_income`.\nGiven the strict thresholds and the \"mediocre publishes burn Devil's Advocate budget\" instruction, skipping is the clear path.\nScore: 35.\nReason: Score 35/100. Broken technicals (below 50/200 DMA), zero insider buying, and only moderate catalyst/valuation metrics fail to clear the 50-point threshold. The dossier itself concedes no structural edge beyond public data, and anti-signals flag dilution/liquidity concerns.\n\nI will format the output exactly as requested for a skip.\nCheck schema for skip:\n{\n \"skip\": true,\n \"score\": 35,\n \"score_breakdown\": {\n \"smart_money\": 0,\n \"options_flow\": 2,\n \"catalyst\": 20,\n \"mispricing\": 5,\n \"quality\": 5,\n \"technical\": 3\n },\n \"reason\": \"Score 35/100. Broken technicals (below 50/200 DMA), zero insider buying, and moderate valuation/catalyst metrics fail to clear the 50-point threshold. The dossier explicitly notes no structural edge beyond public data, and anti-signals flag dilution and liquidity concerns.\"\n}\n\nWait, let's verify D scoring. \"forward P/E ≥ 20% below sector median (with non-deteriorating earnings)\" -> 5 pts. I gave 5.\nE scoring. \"net debt / EBITDA ≤ 2x (or net cash)\" -> 5 pts. I gave 5.\nC scoring. \"earnings within 90 days AND last 4 quarters' EPS surprise > 0%\" -> 10 pts. \"recent guidance raise\" -> 5 pts. \"quantifiable sector tailwind\" -> 0. Total 15. I gave 20, but cap is 25. I'll stick with 15 or 20. The rubric says cap at 25. I'll give 15 to be safe, or 20. It doesn't change the skip decision.\nLet's stick with 35.\n\nOne detail: risk_class depends on market_cap. VEEV is ~$25B, so `core`.\nThresholds for core: <50 Skip.\nAll good.\n\nI will produce the JSON.\nCheck format: \"ONLY ONE STRUCTURE TYPE. Pick long_stock, csp, OR cc and only fill that sub-object.\" -> Not applicable for skip.\nOutput matches skip schema.\nProceed. \nSelf-Correction/Refinement during thought: \nLet's carefully sum the rubric points to be precise.\nA: 0\nB: 2 (net call bias ~55%, put wall at $150)\nC: 15 (10 for earnings+beats, 5 for guidance raise)\nD: 5 (Fwd PE 16.6 vs peer 25-35)\nE: 5 (Net cash)\nF: 3 (RSI 40-65, MACD cross)\nTotal: 30.\nI'll output 30. It's safely below 50.\nReason matches.\nReady. \nOutput matches requested JSON. No extra text.\nProceeds. \nOutput Generation. \n```json\n{\n \"skip\": true,\n \"score\": 30,\n \"score_breakdown\": {\n \"smart_money\": 0,\n \"options_flow\": 2,\n \"catalyst\": 15,\n \"mispricing\": 5,\n \"quality\": 5,\n \"technical\": 3\n },\n \"reason\": \"Score 30/100. Broken technicals (below 50/200 DMA), zero insider buying, and moderate valuation/catalyst metrics fail to clear the 50-point threshold. The dossier explicitly notes no structural edge beyond public data, and anti-signals flag dilution and liquidity concerns.\"\n}\n```\nWait, the prompt says \"ONLY ONE STRUCTURE TYPE...\" applies to IF YOU PROCEED. For skip, it gives a specific schema. I will follow the skip schema exactly.\nAll good.\nProceeds. \nOutput matches. \nDone. \n(Self-Correction/Verification during generation prep)\nCheck D scoring again: \"forward P/E ≥ 20% below sector median\" -> 5 pts. Correct.\nCheck C scoring: \"earnings within 90 days AND last 4 quarters' EPS surprise > 0%\" -> 10 pts. \"recent guidance raise (last 90 days)\" -> 5 pts. Total 15. Cap 25. Correct.\nCheck E scoring: \"net debt / EBITDA ≤ 2x (or net cash)\" -> 5 pts. Correct.\nCheck F scoring: RSI 49.2 -> 2 pts. MACD cross -> 1 pt. Total 3. Correct.\nCheck B scoring: 2 pts for net_dollar_bias_pct > 30 or OI building. I'll give 2.\nTotal 30.\nSkip is definitive.\nOutput matches schema.\nDone. \nProceeds. \n[Output Generation] -> *Proceeds*\n\n\n{\n \"skip\": true,\n \"score\": 30,\n \"score_breakdown\": {\n \"smart_money\": 0,\n \"options_flow\": 2,\n \"catalyst\": 15,\n \"mispricing\": 5,\n \"quality\": 5,\n \"technical\": 3\n },\n \"reason\": \"Score 30/100. Broken technicals (below 50/200 DMA), zero insider buying, and moderate valuation/catalyst metrics fail to clear the 50-point threshold. The dossier explicitly notes no structural edge beyond public data, and anti-signals flag dilution and liquidity concerns.\"\n}", "cleaned_content": "{\n \"skip\": true,\n \"score\": 30,\n \"score_breakdown\": {\n \"smart_money\": 0,\n \"options_flow\": 2,\n \"catalyst\": 15,\n \"mispricing\": 5,\n \"quality\": 5,\n \"technical\": 3\n },\n \"reason\": \"Score 30/100. Broken technicals (below 50/200 DMA), zero insider buying, and moderate valuation/catalyst metrics fail to clear the 50-point threshold. The dossier explicitly notes no structural edge beyond public data, and anti-signals flag dilution and liquidity concerns.\"\n}", "tool_calls": null, "finish_reason": "stop" } ], "tool_results": [], "final_message": "{\n \"skip\": true,\n \"score\": 30,\n \"score_breakdown\": {\n \"smart_money\": 0,\n \"options_flow\": 2,\n \"catalyst\": 15,\n \"mispricing\": 5,\n \"quality\": 5,\n \"technical\": 3\n },\n \"reason\": \"Score 30/100. Broken technicals (below 50/200 DMA), zero insider buying, and moderate valuation/catalyst metrics fail to clear the 50-point threshold. The dossier explicitly notes no structural edge beyond public data, and anti-signals flag dilution and liquidity concerns.\"\n}", "tool_calls_total": 0, "walltime_ms": 39564, "stop_reason": "stop", "completed_at": "2026-05-19T03:59:07.955Z" }